Nasdaq-listed Allogene Therapeutics has hired Earl Douglas as its new general counsel.
Douglas was previously general counsel for Applied Molecular Transport (AMT), a clinical-stage biopharmaceutical company. Before joining AMT, he was vice president and general counsel of Kiverdi and also had spells as general counsel and corporate secretary at BioMimetic Therapeutics (acquired by Wright Medical Group), Spinal Dynamics (acquired by Medtronic) and OPX Biotechnologies (acquired by Cargill).
In addition to his in-house legal work, Douglas was counsel with law firm Wilson Sonsini Goodrich & Rosati, and earlier in his career was an associate with Weil Gotshal & Manges.
During his legal career he has advised management and boards on a range of legal and strategic matters, including corporate governance, SEC filings, commercial transactions, intellectual property strategy, M&A, corporate finance, litigation and compliance programs.
San Francisco, California-based Allogene is a clinical-stage biotechnology company developing products for the treatment of cancer.
David Chang, president, CEO and co-founder of the company, says in a statement: ‘We are excited to welcome Earl who brings a tenure of experience guiding publicly traded biotech companies on complex legal issues, corporate strategy and transactions.
‘I also want to thank Lillian Smith, our interim general counsel, for her exceptional leadership and invaluable contributions as we conducted this search. Her ongoing partnership with Earl will ensure our skilled legal group continues to thrive as we move toward.’
Ben Maiden
Ben Maiden is the editor-at-large of Governance Intelligence, an IR Media publication, having joined the company in December 2016. He is based in New York. Ben was previously managing editor of Compliance Reporter, covering regulatory and compliance...
